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HISTORY OF PRESENT ILLNESS: 61 year-old Hispanic male presents with a one-
month history of a diffuse rash with associated altered mental status, pain and pruritus. 
At the onset of the rash patient was undergoing treatment with ipilimumab and 
nivolumab for cT4NxM1a (stage IV) adenocarcinoma of the lung with metastasis to the 
ipsilateral lung and mediastinum. The patient completed four cycles before stopping 
therapy due to an inpatient psychiatric hospitalization. Thirty-to-sixty days after his last 
immunotherapy cycle, he developed a diffuse rash which continued to worsen, 
prompting dermatology evaluation. 
MEDICAL/SURGICAL HISTORY: Stage IV adenocarcinoma of the lung, stage 3 
CKD, bipolar disorder with suicidal ideations, CAD, Type II DM, HTN, cirrhosis, diastolic 
CHF, previous alcohol abuse
MEDICATIONS: Amlodipine, aspirin, atorvastatin, cholecalciferol, folic acid, 
furosemide, gabapentin, hydroxyzine, insulin, isosorbide mononitrate, melatonin, 
mupirocin, oxcarbazepine, prednisone, prochlorperazine, propranolol, quetiapine, 
thiamine 
PREVIOUS TREATMENTS: Methylprednisolone 1mg/kg BID, eight-week prednisone 
taper beginning at 60mg BID
PHYSICAL EXAMINATION: Diffuse hemorrhagic crusted plaques on upper and 
lower lips. Multiple necrotic, black, crusted, pink-red papules and plaques on chest, 
back, upper extremities, and thighs, worse on extensor and weight-bearing areas. 
Occasional non-blanching, pink papules noted on central back and right thigh.  
Multiple, bleeding ulcerations with violaceous borders on sacral region and buttocks. 
LABORATORY DATA: Glucose 316mg/dL (65-99), Cr 2.0mg/dL (0.53-1.30), Na 
127mmol/L (135-145), Albumin 2.8g/dL (3.5-4.8), AST 62U/L (<41), GFR 35mL/
min/1.73m2 (>60), PT 16.6 sec (12-14.6), NT-proBNP 839pg/mL (<125), CBC, 
remaining CMP all WNL.
STUDIES: CT chest, abdomen and pelvis on 11/2018 showed multiple small 
pulmonary nodules are stable to slightly decreased in size since previous exam. 
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BIOPSY: Health Network Laboratories (S18-50470, 11/10/18) Central back and right 
thigh: “interface dermatitis with eosinophils; superficial impetiginization.”
Mayo Medical Laboratories (S18-50470, 11/10/18) Central back DIF: “continuous 
strong linear deposition of IgG and C3 along the BMZ. Scattered and clumped cytoids of 
IgM and IgA in the papillary dermis. Continuous strong shaggy deposition of fibrinogen 
along the BMZ.”
Lichen planus pemphigoides is an autoimmune disease that is thought to be a 
combination of lichen planus and bullous pemphigoid. It is initiated by lichen planus 
causing damage to the epidermis and dermoepidermal junction which releases hidden 
antigens. These antigens lead to circulating IgG antibodies against portions of the 
basement membrane. The most common antibody is against the MCW-4 epitope of the 
NC16A4 domain of BPAg2, but several others have been reported.
Lichen planus pemphigoides is characterized by bullous lesions appearing within 
previous lichen planus sites as well as on normal skin. Histopathologically, both H&E and 
DIF of the lesions will either show evidence of lichen planus, bullous pemphigoid or a 
combination of the two. 
There are several associations reported with lichen planus pemphigoides. Many cases 
are idiopathic, but medications such as ACE inhibitors, simvastatin, PD-1 inhibitors, and 
antituberculous drugs as well as PUVA, sun exposure, pregnancy, and, rarely, malignancy 
have also been reported as causes. 
Therapy with immune checkpoint inhibitors, such as PD-1, PD-L1, and CTLA-4 
inhibitors, is a rare cause of lichen planus pemphigoides, but commonly causes 
cutaneous toxicity. The most common manifestations are pruritus and a morbilliform 
eruption. However, lichenoid reactions, psoriasis, acneiform eruptions, vitiligo, 
sarcoidosis, bullous pemphigoid, dermatomyositis, and alopecia areata have also been 
reported. While each medication has the propensity for this toxicity by itself, combination 
CTLA-4 and PD-1 inhibitors have been implicated in the development of earlier, more 
frequent and more severe reactions.
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Figure 1: Erosions and crusted lesions of LPP Figure 2: Lichen planus lesions with hemorrhage
Figure 3: Mucosal involvement of LPP Figure 4: H&E highlighting lichen planus 
changes with dermo-epidermal clefting and 
eosinophils
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